required for adaptive immunity, for example antigen-specific antibody production and allograft rejection. 6 In inflammatory bowel disease, CD40L-positive platelets have been shown to adhere to mucosal microvascular endothelium in vivo, where they trigger or amplify a pro-inflammatory response. 11 Platelets also secrete soluble CD40L (sCD40L), which in sickle cell anaemia is elevated in plasma and biologically active. It therefore contributes to the induction of B cells, tissue factor and inter-Cellular adhesion molecule 1 (ICAM-1),
suggesting that sCD40L may add to the chronic inflammation and increased thrombotic activity known to occur in this disorder. 12 sCD40L interacts with another protein, type I transmembrane receptor CD40, which is expressed on platelet activation but is also present on monocytes/macrophages and endothelial cells. The sCD40L-CD40 interaction in this context promotes monocyte adhesion to vascular endothelium, endothelial activation and expression of leukocyte adhesion molecules. 8 Platelets have been shown to activate dendritic cells through the expression of CD40L in both in vitro and in vivo mouse models. Thus, through the co-stimulatory activity of dendritic cells, platelets are able to regulate T-and B-cell responses. 13 Although the clinical significance of these observations has not yet been determined, it is interesting to note that increased expression of platelet activation markers, including CD40L, can be detected in several diseases with T-and B-cell components. These include inflammatory bowel disease, atherosclerosis, diabetes and systemic lupus erythematosus. 13 An activating capability of oxidised low-density lipoprotein (LDL) cholesterol on platelets mediated by the platelet receptor CD36 has recently been described. This is an interesting relationship between platelets and the chronic inflammatory feature of atherosclerosis.
14 This activation can be further augmented by endothelial-cell-derived microparticles, which also bind and activate platelets via CD36. 15 Besides hyperlipidemia, two other mechanisms might link obesity or the metabolic syndrome to thrombosis. The first is mediated by leptin, a hormone that regulates energy intake and is structurally and functionally related to cytokines. Leptin can enhance platelet aggregation when present in high concentrations, such as those observed in obese individuals. 16, 17 A second mechanism is observed in central obesity and involves insulin resistance. Platelets physiologically express insulin receptors. Insulin decreases the sensitivity of circulating platelets to agonists and platelet deposition under high shear rate conditions. 18 This may be why platelets from patients with diabetes or those who are obese are less sensitive to the antiaggregating effects of insulin. 19 Another pathway linking innate immunity, haemostasis and thrombosis is the activation of a complement by platelets or platelet microparticles, supposedly through the expression of the C1q receptor on the platelet surface and the expression of P-selectin. 7 The complement-activated components C3a and C5a are potent pro-inflammatory agents. The terminal complement complex C5b-9 has platelet-and endothelialactivating properties at sublytic concentrations. 7 The platelet chemokine platelet factor-4 (PF-4) and beta-thromboglobulins have an important, although diversified, role in innate immunity as well as an established and well-known role in haemostasis. 20, 21 They are the synthesises the tissue factor pathway inhibitor, which binds and inhibits the tissue factor-activated factor VII-activated factor X complex. 22 Cytokines derived from activated leukocytes during inflammation downregulate the endothelial receptors and upregulate leukocyte adhesion molecules, while proteases from leukocytes cleave thrombomodulin and glycosaminoglycans from the endothelial surface. 23 The net result is that the endothelium is tipped towards being a procoagulant, pro-inflammatory surface. At the same time, cytokines such as TNF-α and interleukin-1 (IL-1) induce tissue factor expression on monocytes and the endothelium, favouring unopposed thrombin formation. 23 Thrombin in turn has several pro-inflammatory activities. It induces the expression of P-selectin and the secretion of plateletactivating factor by the endothelium. It is chemotactic for leukocytes. It also stimulates the production of monocyte chemotactic protein-1, IL-6
and IL-8. 24 The inflamed endothelium loses its barrier function so leukocytes can extravasate in the extraluminal space. This is an initial step that occurs in chronic inflammatory diseases of vessel walls, such as atherosclerosis or vasculitis. 25 In vasculitis, immune complexes that bind to the endothelium and trigger an upregulation of leukocyte adhesion molecules may be a source of arterial injury, initiating endothelial inflammation and atherosclerosis. 26 Downregulation of thrombomodulin and endothelial protein C receptor was reported in the mucosal microvessels of patients suffering from inflammatory bowel disease. 27 It might contribute to ischaemia and necrosis of the intestinal mucosa. 27 Patients with inflammatory bowel disease also develop thrombosis in vessels that are far from the gut. They have a more than three-fold higher risk of venous thrombosis than the control population or patients with other chronic bowel diseases, such as coeliac disease. 28 The proposed mechanism is that tissue-factor-carrying microparticles or cells generated by inflammatory stimuli in the intestinal circulation eventually reach the systemic circulation and are the trigger for thrombosis. 29 Another important effector of inflammation is tissue hypoxia. Besides exerting a proangiogenic effect through upregulation of vascular endothelial growth factor, hypoxia determines a complex procoagulant response mediated by several cellular mechanisms. 30 Oxidative stress, mediated by leukocytes and bacteria, also shifts the haemostatic balance. One specific and well-described mechanism, for example, is the oxidation of methionine 388 in thrombomodulin. This is known to slow the rate at which the thrombomodulin-thrombin complex activates protein C. It has been shown to be a potential mechanism of hypercoagulability in patients with diabetes and in those who smoke.
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Haemostasis and ImmunityAn Evolutionary Perspective
That haemostasis, inflammation and innate immunity are tightly linked is not so surprising. These defense mechanisms have developed together and were a single entity before vertebrates evolved. In the horseshoe crab, an invertebrate model for the study of the evolution of coagulation, external 'agents' disrupting its integrity activate a cell, called the amebocyte, which functions as both a platelet and a macrophage. 32 The amebocyte degranulates on activation, releasing proteins that react to form an insoluble clot. At this point it releases a substance with antibacterial properties -a vestigial form of innate immunity. The result is the 'clotting out' and destruction of the disturbing agent. 32 Vertebrates have evolved separate clotting and inflammatory immune systems that can co-operate and interact. Most of the inflammatory signals responsible for immune activation will also precipitate procoagulant signals.
Conversely, the coagulation system rapidly feeds back and upregulates the innate immune response. 33, 34 Anticoagulants possess several anti-inflammatory properties, which have been exploited therapeutically in settings such as severe sepsis. [35] [36] [37] Their anti-inflammatory properties are independent of their antithrombotic action, as shown in the case of protein C by results obtained in animal sepsis models after separating the anticoagulant from the anti-inflammatory function. 38 The interaction between inflammation, haemostasis and immunity is schematically represented in Figure 1 .
Inflammation, Ageing and Thrombosis
In recent years it has become clear that ageing is associated with a low-grade persistent inflammatory response that has been termed inflamm-ageing. 39, 40 Coagulation factors and pro-inflammatory cytokines
Inflammation and Thrombosis -Brothers in Arms 43 In healthy centenerians this low-grade inflammatory response is associated with anti-inflamm-ageing, i.e. with biological mechanisms that control inflammation. 39, 40 The natural conclusion from these experimental observations is that excess inflammation is a noxious impediment to healthy ageing. It is not currently known whether this low-grade chronic inflammation and coagulation activation is directly linked to the increasing incidence of thrombosis, both arterial and venous, with age (the risk doubles for every decade after 40 years of age). 44 It is likely, however, that in ageing -as in the chronic diseases mentioned -persistent inflammation is a predisposing factor for thrombosis. It is also plausible that other intervening precipitating factors common in the elderly population, such as cardiovascular disease, cancer and metabolic derangement, trigger the thrombotic events.
Comments and Perspectives
Anti-inflammatory agents have traditionally been commonly used in antithrombotic therapy: both aspirin and heparins possess anti-inflammatory activity. 45, 46 However, aspirin, is often used at antiplatelet dosages that do not elicit an anti-inflammatory effect (i.e. do not inhibit cyclo-oxygenase-2 [COX-2]). 
